Correlation of plasma concentration and adverse effects of bosutinib: standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia

被引：0
|
作者：
Akiko Mita
Maiko Abumiya
Masatomo Miura
Takenori Niioka
Saori Takahashi
Tomoko Yoshioka
Yoshihiro Kameoka
Naoto Takahashi
机构：
[1] Akita University Graduate School of Medicine,Department of Hematology, Nephrology, and Rheumatology
[2] Akita University Hospital,Department of Pharmacy
[3] Akita University Hospital,Clinical Research Promotion and Support Center
来源：
Experimental Hematology & Oncology | / 7卷
关键词：
Bosutinib; Diarrhea; Liver dysfunction; Trough concentration; Chronic myeloid leukemia;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Lower-Initiating Dose of Bosutinib for Resistant or Intolerant to Prior Therapy Chronic Myeloid Leukemia Patients (BOGI trial): A Single-Arm, Multicenter, Phase II Trial
    Ureshino, Hiroshi
    Takahashi, Naoto
    Ikezoe, Takayuki
    Takamori, Ayako
    Kawaguchi, Atsushi
    Ichinohe, Tatsuo
    Kimura, Shinya
    BLOOD, 2023, 142
  • [42] Matching-Adjusted Indirect Treatment Comparison of Bosutinib, Dasatinib, Nilotinib and Ponatinib on Survival for Second Line Chronic Phase Chronic Myeloid Leukemia Patients
    Muresan, Bogdan
    Mamolo, Carla
    Cappelleri, Joseph C.
    Shapiro, Mark
    Crescenzo, Rocco J.
    Su, Yun
    Heeg, Bart
    BLOOD, 2016, 128 (22)
  • [43] Gonadotoxic Effects of Nilotinib in Chronic Myeloid Leukemia Treatment Dose in a Mouse Model
    Seval, Guldane Cengiz
    Ozkavukcu, Sinan
    Seval, Murat
    Ayli, Meltem
    TURKISH JOURNAL OF HEMATOLOGY, 2017, 34 (02) : 137 - 142
  • [44] DOSE-ESCALATION AND PHARMACOKINETICS (PK) OF DIFFERENT LENALIDOMIDE (LEN) STARTING DOSE REGIMENS IN PATIENTS WITH RELAPSED OR REFRACTORY (REL/REF) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) (CC-5013-CLL-009)
    Wendtner, C.
    Hallek, M.
    Fraser, G.
    Michallet, A.
    Hillmen, P.
    Duerig, J.
    Gregory, S.
    Kalaycio, M.
    Aurran-Schleinitz, T.
    Trentin, L.
    Stilgenbauer, S.
    Kipps, T.
    Purse, B.
    Zhang, J.
    Chen, N.
    Mei, J.
    Chanan-Khan, A.
    HAEMATOLOGICA, 2013, 98 : 41 - 42
  • [45] The current role of high-dose imatinib in chronic myeloid leukemia patients, newly diagnosed or resistant to standard dose
    Breccia, Massimo
    Alimena, Giuliana
    EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (13) : 2075 - 2087
  • [46] Observational, Retrospective and Multicenter Analysis of Spanish CML Group, in Patients with Chronic Myeloid Leukemia in Treatment-Free Remission after Discontinuation of Bosutinib
    Langdon, Gonzalo Maortua
    De Paz, Raquel
    Giraldo, Pilar
    Xicoy, Blanca
    Lopez, Joaquin Martinez
    Carrascosa, Guiomar Bautista
    Alonso, Jose Maria Alonso
    Pereira, Maria Soledad Noya
    Pacho, Magdalena Sierra
    Lopez, Raul Perez
    Gerosa, Silvana Daniela Saavedra
    De Soria, Valle Gomez G.
    de las Heras, Natalia
    Gutierrez Sr, Valentin Garcia
    BLOOD, 2024, 144 : 6604 - 6605
  • [47] Efficacy of Imatinib Dose Escalation in Patients With Chronic Myeloid Leukemia in Chronic Phase (vol 115, pg 551, 2009)
    Kantarjian, H. M.
    Larson, R. A.
    Guilhot, F.
    O'Brien, S. G.
    Mone, M.
    Rudoltz, M.
    Krahnke, T.
    Cortes, J.
    Druker, B. J.
    CANCER, 2010, 116 (15) : 3750 - 3750
  • [48] A phase I dose-escalation study of clofarabine in combination with fractionated gemtuzumab ozogamicin in patients with refractory or relapsed acute myeloid leukemia
    Foster, Matthew C.
    Amin, Chirag
    Voorhees, Peter M.
    Van Deventer, Hendrik W.
    Richards, Kristy L.
    Ivanova, Anastasia
    Whitman, Jennifer
    Chiu, Wingkeung Michael
    Barr, Nathan D.
    Shea, Thomas
    LEUKEMIA & LYMPHOMA, 2012, 53 (07) : 1331 - 1337
  • [49] The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study
    Martinez-Lopez, Joaquin
    Mustjoki, Satu
    Porkka, Kimmo
    Klisovic, Rebecca B.
    Wolf, Dominik
    Busque, Lambert
    Hernandez-Boluda, Juan Carlos
    Swanink, Rene
    Martin Regueira, Patricia
    Lipton, Jeffrey H.
    LEUKEMIA & LYMPHOMA, 2021, 62 (08) : 2040 - 2043
  • [50] Asciminib Enhances Its Treatment Efficacy Synergistically in the Treatment of Chronic Myeloid Leukemia Harboring ABL1 Kinase Domain Mutation When Combined with a Reduced Dose of Ponatinib, Dasatinib, or Bosutinib, but Not with Nilotinib or Imatinib
    Han, Ho-Jae
    Kim, Jaeyoon John
    Pyne, Danielle
    Travas, Anthea
    Ambalavanan, Amirthagowri
    Kimura, Shinya
    Deininger, Michael W.
    Kim, Jong-Won
    Kim, Dennis D. H.
    BLOOD, 2023, 142
12345